# Artificial Intelligence in Diabetes Management Market > AI in Diabetes Management Market Research Report Information by Type (Diagnostics, Treatment Planning, Data Management, and Patient Self-Management), By Deployment (Cloud-Based, On-Premises, Hybrid), By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes.),By End User(Hospitals and Clinics, Ambulatory Surgical Centers, Diabetes Treatment Centers, Patients) By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) - Forecast to 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 22.76% - **2024:** $ 1,568.64 Million - **2025:** $ 1,925.66 Million - **2035:** $ 14,239.56 Million - **Key Players:** Companies such Eli Lilly and Company, AstraZeneca, Sanofi, Novo Nordisk A/S, Tandem Diabetes Care, Inc., F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Dexcom, Inc., Insulet Corporation are some of the major participants in the global market. **Report ID:** MRFR/HC/25230-CR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** June 26, 2026 **URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-diabetes-management-market-26893 --- ## Market Summary ## Artificial Intelligence in Diabetes Management Market Overview As per MRFR analysis, the AI in Diabetes Management Market Size was estimated at 1.19 (USD Billion) in 2024. The AI in Diabetes Management Market Industry is expected to grow from 1.50 (USD Billion) in 2025 to 12.23 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 26.26% during the forecast period (2025 - 2034). ### **Key Artificial Intelligence in Diabetes Management Market Trends Highlighted** Increasing prevalence of diabetes globally, particularly among the elderly population. Growing demand for personalized and real-time diabetes management solutions. Technological advancements in artificial intelligence (AI) and machine learning algorithms. Integration of AI in wearable devices and smartphone applications for continuous glucose monitoring and insulin delivery. Development of AI-powered virtual assistants to provide personalized advice and support to diabetes patients. Partnerships between healthcare providers and technology companies to create AI-driven diabetes management platforms. Shift towards cloud-based AI solutions for data storage and processing, improving accessibility and scalability. Increased focus on AI-powered predictive analytics to identify and manage diabetes-related complications. Emerging trend of using AI in closed-loop systems for automated insulin delivery, offering greater control and convenience to patients. ## Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ## **Artificial Intelligence in Diabetes Management Market Drivers** ### **Rising Prevalence of Diabetes and Obesity** The increasing prevalence of diabetes and obesity globally is a significant driver of the growth of the artificial intelligence in diabetes management market. Diabetes is a chronic metabolic disorder characterized by elevated blood glucose levels, which can lead to various health complications. According to the International Diabetes Federation, an estimated 537 million adults worldwide were living with diabetes in 2021, and this number is projected to reach 783 million by 2045. Obesity, a major risk factor for diabetes, is also on the rise, with approximately 650 million adults worldwide classified as obese in 2023. The growing prevalence of these conditions underscores the need for effective diabetes management solutions, driving the demand for AI-powered technologies that can assist in disease prevention, early detection, personalized treatment, and improved health outcomes. ### **Technological Advancements in AI and Machine Learning** The overall uptake of artificial intelligence in diabetes management is rapidly increasing across the entire industry. This is primarily due to rapid advancements and miniaturization in the field of artificial intelligence and machine learning technologies. These technologies can process large amounts of data, identify patterns and predict, which makes them useful for a variety of diabetes management tasks. Machine learning algorithms can analyze patient data, such as electronic health records, glucose monitoring data and patient lifestyle information to develop personalized treatment plans and predict the risk of complications. Artificial intelligence can also be used to automate several aspects of information processing, such as data entry and generating reminders and educational information. ### **Government Initiatives and Healthcare Reforms** Government initiatives and healthcare reforms aimed at improving diabetes care are driving the adoption of AI in diabetes management. Many governments worldwide have recognized the importance of addressing the growing burden of diabetes and are implementing strategies to promote early detection, prevention, and effective management of the condition. These initiatives often include funding for research and development of AI-based solutions, as well as policies that encourage the adoption of these technologies in healthcare settings. Additionally, healthcare reforms focused on improving patient outcomes and reducing costs are creating a favorable environment for the adoption of AI in diabetes management, as these technologies have the potential to enhance the efficiency and effectiveness of healthcare delivery. ## **Artificial Intelligence in Diabetes Management Market Segment Insights** ### **Artificial Intelligence in Diabetes Management Market Type Insights  ** Diagnostics held the largest revenue share in 2023, due to the growing need for accurate and timely diagnosis of diabetes. The increasing prevalence of diabetes and the need for early detection are driving the growth of this segment. Treatment planning is expected to witness the fastest growth rate over the forecast period, owing to the increasing adoption of AI-powered solutions for personalized treatment planning and optimization. Data Management is also expected to grow significantly, due to the rising need for efficient and secure management of large volumes of patient data. Patient self-management is expected to gain traction as AI-based solutions empower patients to actively participate in their own care and self-manage their condition. The global artificial intelligence in diabetes management market is expected to reach USD 54.23 billion by 2026, exhibiting a CAGR of 30.4% during the forecast period. Source: Primary Research, Secondary Research, MRFR Database and Analyst Review ### **Artificial Intelligence in Diabetes Management Market Application Insights** The application segment can be classified into Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes. Among these, Type 2 Diabetes holds the largest market share due to its high prevalence and increasing incidence rates. The global artificial intelligence in diabetes management market for Type 2 Diabetes is expected to reach USD 156.5 billion by 2024, exhibiting a CAGR of 39.2% during the forecast period. Type 1 Diabetes, though less prevalent than Type 2 Diabetes, is also a significant contributor to the market growth. The increasing adoption of AI-powered insulin delivery systems and continuous glucose monitoring devices is driving the growth of the Type 1 Diabetes segment. Gestational Diabetes, a temporary condition that occurs during pregnancy, is another key application segment in the global artificial intelligence in diabetes management market. The rising prevalence of gestational diabetes and the growing awareness of its potential long-term health implications are fueling the demand for AI-based solutions in this segment. Overall, the application segment in the global artificial intelligence in diabetes management market is expected to witness significant growth in the coming years, driven by the increasing prevalence of diabetes, technological advancements, and rising healthcare expenditure. ### **Artificial Intelligence in Diabetes Management Market Deployment Insights** The deployment segment plays a crucial role in determining the global artificial intelligence in diabetes management market revenue. Cloud-based deployment is projected to dominate the market with a significant market share. The rising adoption of cloud computing services, owing to their cost-effectiveness, flexibility, and scalability, drives the growth of the cloud-based segment. On-premise deployment is expected to hold a considerable share of the market. Healthcare providers prefer on-premise deployment due to concerns regarding data security and privacy. Software as a Service (SaaS) is gaining popularity as it eliminates the need for hardware and software installation and maintenance. The Global Artificial Intelligence In Diabetes Management Market is expected to witness substantial growth over the forecast period, influenced by the increasing prevalence of diabetes and the adoption of advanced technologies for diabetes management. ### **Artificial Intelligence in Diabetes Management Market End User Insights** The global artificial intelligence in diabetes management market is segmented into various end users, including hospitals and clinics, ambulatory surgical centers, diabetes treatment centers, and patients. Among these segments, hospitals and clinics are expected to hold a significant share of the market in the coming years due to the increasing adoption of AI-powered solutions for diabetes management. In 2024, the global artificial intelligence in diabetes management market for hospitals and clinics is projected to reach USD 10.23 billion, exhibiting a CAGR of 35.4% from 2023 to 2032. The growing prevalence of diabetes and the need for efficient disease management drive this market growth. ### **Artificial Intelligence in Diabetes Management Market Regional Insights** The global artificial intelligence in diabetes management market is segmented into North America, Europe, APAC, South America, and MEA. North America is the largest regional segment, accounting for over 40% of the global market revenue. The region has a high prevalence of diabetes, leading to a high demand for advanced diabetes management solutions. Europe is the second-largest regional segment, with a market share of over 30%. The region has a well-established healthcare infrastructure and a growing number of patients with diabetes. APAC is the fastest-growing regional segment, with a market size of over USD 20 billion in 2023 and is projected to reach USD 100 billion by 2032, growing at a CAGR of over 20%. The region has a large population with a high risk of developing diabetes, and governments are investing heavily in healthcare infrastructure to meet the growing demand for diabetes management solutions. South America and MEA are relatively smaller regional segments, but they are expected to witness significant growth in the coming years due to the increasing prevalence of diabetes and the growing adoption of AI-powered healthcare solutions. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **Artificial Intelligence in Diabetes Management Market Key Players and Competitive Insights** Major players are investing heavily in research and development to gain a competitive edge. They are also forming strategic partnerships and collaborations to enhance their product offerings and expand their market reach. Leading market players are focusing on developing innovative and user-friendly solutions that can help patients manage their diabetes more effectively. The artificial intelligence in diabetes management market is expected to witness significant growth in the coming years, driven by the increasing prevalence of diabetes and the growing adoption of AI technology in healthcare. The competitive landscape is expected to remain highly competitive, with new entrants and established players vying for market share. A prominent player in this industry is Glooko, Inc. The company offers a comprehensive diabetes management platform that includes a mobile app, a web portal, and a cloud-based data management system. Glooko's platform allows patients to track their blood glucose levels, medication, and diet, and provides them with personalized insights and recommendations. The company also offers a range of educational resources and support services to help patients manage their diabetes. Another competitor in the market is Dexcom, Inc. The company offers a continuous glucose monitoring (CGM) system that allows patients to track their blood glucose levels in real-time. Dexcom's CGM system is integrated with a mobile app that provides patients with personalized insights and recommendations. The company also offers a range of other products and services, including insulin pumps, glucose meters, and diabetes management software. Dexcom is a leading player in the CGM market and is well-positioned to benefit from the growing adoption of AI technology in diabetes management. ### **Key Companies in the Artificial Intelligence in Diabetes Management Market Include** ## **Artificial Intelligence in Diabetes Management Market Developments** The global artificial intelligence in diabetes management market size was valued at USD 1.19 billion in 2024 and is expected to expand at a compound annual growth rate (CAGR) of 26.26% from 2025 to 2034. The market growth is attributed to the rising prevalence of diabetes, increasing adoption of AI-powered diabetes management solutions, and government initiatives to promote AI in healthcare. Key players in the market include Google, IBM, Microsoft, and Roche. Recent advancements include the development of AI-powered insulin delivery systems and AI-enabled diabetes monitoring devices. ## **Artificial Intelligence in Diabetes Management Market Segmentation Insights** ### **Artificial Intelligence in Diabetes Management Market Type Outlook** ### **Artificial Intelligence in Diabetes Management Market Application Outlook** ### **Artificial Intelligence in Diabetes Management Market Deployment Outlook** ### **Artificial Intelligence in Diabetes Management Market End User Outlook** ### **Artificial Intelligence in Diabetes Management Market Regional Outlook** ## Market Drivers ### Rising Global Diabetes Prevalence AI is proven transformative in addressing these challenges, offering personalized treatment planning and real-time disease monitoring. For example, AI-driven platforms combine continuous glucose monitoring (CGM) and wearable technologies, enabling patients and clinicians to better control blood glucose levels and minimize complications.   In China, AI-powered systems guide lifestyle modification, medication adjustments, and insulin delivery, reportedly improving self-management and adherence. Globally, AI algorithms are being used for automated retinal screening to detect diabetic retinopathy, predicting individual risk for diabetes, and optimizing drug prescriptions using machine learning techniques. ### Advancements in Connected Devices and Digital Health Infrastructure Advancements in connected devices and digital health infrastructure have emerged as crucial drivers for the global adoption and effectiveness of [artificial intelligence](https://www.marketresearchfuture.com/reports/artificial-intelligence-market-1139) (AI) in diabetes management. Technologies such as continuous glucose monitors (CGMs), smart insulin pens, AI-enabled smartwatches, and integrated mobile health applications are fundamentally transforming patient engagement, glycemic control, and treatment adherence.   Wearables like Perspirion Diagnostics’ sweat-based glucose monitors and Daia Health’s emergency alert app further exemplify how digital infrastructure enhances safety, self-management, and real-time responsiveness for diabetics. ## Future Outlook The AI in Diabetes Management Industry size is projected to reach USD 14,239.56 million by 2035, growing at a CAGR of 22.76%, driven by increasing demand for high-performance computing and enhanced security features. **New opportunities:** - Expansion of Remote Patient Monitoring (RPM) and Telehealth - Emergence of Generative AI and Predictive Analytics - Partnerships Between Tech Giants and Healthcare Providers. By 2035, theAI in Diabetes Management Industry is expected to be robust, driven by innovation and strategic partnerships. ## Segment Insights ### By Type: Diagnostics (Largest) vs. Treatment Planning (Fastest-Growing) In the AI in Diabetes Management Market, the diagnostics segment dominates the gloal market, accounting for the largest share of 63.2%. This segment encompasses advanced AI tools that facilitate accurate and early detection of diabetes-related complications, leading to better patient outcomes. Treatment planning follows as a prominent area, leveraging AI to customize treatment strategies based on individual patient data, thereby improving the effectiveness of diabetes management. Algorithms: Diagnostics (Dominant) vs. Treatment Planning (Emerging) The diagnostics segment leverages advanced algorithms to analyze data from various sources, such as wearable devices and medical records, allowing healthcare professionals to diagnose diabetes-related issues timely and effectively. In contrast, the treatment planning segment is emerging as a critical component in the management of diabetes, using AI algorithms to create tailored treatment plans for patients. This segment focuses on analyzing large datasets to propose optimal medication and lifestyle adjustments, thereby enhancing patient adherence and health outcomes during the diabetes management process. ### By Application: Type 2 Diabetes (Largest) vs. Type 1 Diabetes (Fastest-Growing) In the AI in Diabetes Management Market, Type 2 Diabetes holds the largest share among the application segments, accounting for 72.5% of the market. This dominance stems from the growing prevalence of Type 2 Diabetes globally, leading to increased demand for intelligent management solutions that can personalize treatment protocols. The widespread acceptance of these solutions among healthcare providers and patients further solidifies its market position, making Type 2 Diabetes the primary focus for AI applications in diabetes management. On the other hand, Type 1 Diabetes represents the fastest-growing segment in this market. As advancements in technology drive innovations in AI applications, solutions tailored specifically for Type 1 Diabetes are gaining traction. Factors such as rising awareness about diabetes management, the need for continuous monitoring, and the swift adaptation of AI technology in medical settings contribute to the rapid growth of this segment. This dual trend of dominance and growth encapsulates the dynamic nature of the global market dynamics in diabetes management. Type 2 Diabetes: Dominant vs. Type 1 Diabetes: Emerging Type 2 Diabetes currently stands as the dominant application segment within the global market, leveraging a robust framework of established data analytics and personalized care solutions. These solutions utilize AI algorithms that analyze various health parameters, leading to proactive monitoring and improved patient outcomes. The integration of wearables and mobile applications has enhanced patient engagement, making management more interactive and effective. Conversely, Type 1 Diabetes, classified as an emerging segment, shows significant potential for growth. Innovations such as automated insulin delivery systems and continuous glucose monitoring powered by AI illustrate the market's shift towards tailored management for Type 1 patients. The recent emphasis on real-time data analysis and machine learning ensures that Type 1 Diabetes management solutions are not just reactive but predictive, thus improving the overall quality of life for patients. ### By Deployment: Cloud-Based (Largest) vs. Software as a Service (SaaS) (Fastest-Growing) In the AI in Diabetes Management Market, the Deployment segment showcases a dynamic landscape, with Cloud-Based solutions holding the largest market share at 61.7%. Enterprises increasingly prefer cloud solutions due to their scalability, accessibility, and cost-effectiveness, making them a dominant choice for diabetes management applications. In contrast, Software as a Service (SaaS) is emerging rapidly, appealing to healthcare providers who favor subscription models that reduce upfront investments while ensuring continuously updated AI technologies. Deployment: Cloud-Based (Dominant) vs. On-Premise (Emerging) Cloud-Based deployment stands out as the dominant choice due to its ability to enable real-time data processing and remote monitoring, essential for managing diabetes effectively. It supports vast data storage and seamless integration with various health systems, enhancing patient outcomes through timely interventions. On-Premise solutions, while offering higher data security and control, are seeing a steady emergence as organizations seek tailored implementations that align closely with their existing IT infrastructure. However, the flexibility and innovation associated with Cloud-Based systems position it favorably as the cornerstone for future advancements in AI applications for diabetes management. ### By End User: Hospitals and Clinics (Largest) vs. Diabetes Treatment Centers (Fastest-Growing) In the AI in Diabetes Management Market, Hospitals and Clinics represent the largest end-user segment, accounting for 66.1% of the market and leveraging advanced technologies for patient care and management. This segment dominates due to its comprehensive resources and integration of AI for monitoring and treatment, capturing a significant portion of the market. On the other hand, Diabetes Treatment Centers are emerging as a fast-growing segment, focused on specialized care and personalized treatment approaches, driven by increasing patient awareness and the need for advanced diabetes management solutions. The growth trends within this segment are driven by the rising prevalence of diabetes worldwide and the growing adoption of AI technologies in various healthcare settings. Hospitals and Clinics continue to invest in AI-driven systems to enhance patient outcomes and operational efficiency, while Diabetes Treatment Centers rapidly expand their services through innovative AI applications. The emphasis on personalized medicine and improved patient engagement is boosting the growth of both segments, with a significant shift towards outpatient care and personalized diabetes management solutions. Hospitals and Clinics (Dominant) vs. Diabetes Treatment Centers (Emerging) Hospitals and Clinics represent the dominant force in the global market, providing extensive services that integrate AI for comprehensive patient management. These institutions typically have robust resources and infrastructure, enabling them to utilize AI-driven tools for diagnostics, real-time monitoring, and personalized treatment plans. The dominance of this segment is characterized by established practices, extensive patient networks, and ongoing investments in technology to enhance care delivery. In contrast, Diabetes Treatment Centers are emerging as a key player focusing on specialized diabetes care, often tailored to individual patient needs. These centers harness AI technology to refine treatment protocols and facilitate continuous patient engagement, thus redefining diabetes management strategies. With their adaptive approaches, these centers are growing swiftly in terms of both patient numbers and service offerings. ## Regional Market Share Analysis **North America: Fastest growing diabetes management** North America leads in the AI in Diabetes Management Market size, accounting for over 45% of the global revenue in 2024. North America leads the global market, driven by high prevalence, advanced healthcare infrastructure, and heavy investment in cloud-based platforms. The region commands over 40% market share, with rapid adoption in hospitals, clinics, and patient apps amid rising Type 2 and gestational cases. - According to the Centers for Disease Control and Prevention, over 38.4 million Americans were living with diabetes in 2024, while approximately 97.6 million adults had prediabetes. The increasing burden of chronic metabolic diseases and strong digital health adoption are significantly accelerating demand for AI-powered diabetes monitoring and predictive analytics platforms throughout North America. Primary care clinics favor hybrid models, with Doctors App-like EMRs in urban centers streamlining T2D workflows. Canadian clinics leverage AI for gestational diabetes (GDM) screening, where models like ANN predict risk at 83% sensitivity using BMI and glucose data. Over 60% of U.S. endocrinologists report AI boosts efficiency. Patients access apps like mySugr for photo-based carb logging and real-time TIR coaching, improving adherence by 50%. Wearables (Dexcom G7) feed AI for personalized dosing, with RCTs showing 1-2% HbA1c drops. Accessibility shines in underserved areas via low-cost cloud sync. **Europe: Strong Production diabetes management** Europe AI in Diabetes Management Market size was valued at USD 392.16 million in 2024, making it the second-largest regional market with a 25% share. In Europe, holds a strong position in the global AI diabetes management market, with approximately 25% share driven by robust healthcare systems, EU-wide digital health initiatives, and stringent data regulations like GDPR. - According to the World Health Organization European health estimates, more than 60 million people across Europe are currently living with diabetes, creating substantial demand for AI-enabled monitoring and predictive care technologies. Expanding adoption of connected healthcare systems and data-driven disease management solutions continues supporting strong regional market growth. The region benefits from high diabetes prevalence over 60 million cases and leaders like Germany, UK, France, and Netherlands pioneering AI integration in diagnostics, monitoring, and care. European hospitals favor cloud-hybrid systems compliant with GDPR and eHealth standards. Platforms like Glooko connect 200+ devices to EMRs, enabling population dashboards for TIR tracking across wards. Glytec-like dosing AI reduces errors by 70% in ICUs, with ROI from shorter stays. EU projects like AI4Health fund on-premises options for data sovereignty in networks like Charité Berlin. **Asia Pacific: Expanding diabetes management** Asia Pacific commands a rapidly expanding share of the global AI in diabetes management market, fueled by massive diabetes prevalence, smartphone penetration, and government-backed digital health initiatives. The region, with nearly half the world's cases (over 250 million), drives explosive growth through affordable wearables, cloud platforms, and AI predictive tools tailored to diverse populations. Hospitals dominate with 58% market share, using cloud EMRs for AI glucose dashboards. Apollo in India deploys analytics for risk stratification; Singapore/Australia clinics integrate CGMs with population tools. Software platforms hold 42.8% segment share, enabling real-time TIR tracking and complication alerts. **South America: Growing diabetes management** South America faces a surging diabetes burden, with AI management systems emerging as cost-effective solutions amid limited resources and high prevalence. The region trails North America and Europe in adoption but shows promise through mobile-first cloud platforms and public health pilots targeting Type 2 dominance. Public hospitals adopt hybrid cloud-on-premises systems for affordability. Platforms sync CGM data to dashboards, reducing ICU hypo events by 30-50%. Local servers process high-volume T2D cohorts, with FHIR enabling EMR ties despite legacy challenges. Clinics prioritize mobile apps for self-management, with AI bolus calculators and photo-carb logging boosting TIR 10-15%. Patients in urban favelas use free WhatsApp bots for reminders; rural telemedicine cuts travel via satellite-linked wearable. **Middle East & Africa: Emerging diabetes management** In Middle East & Africa (MEA) represent an emerging frontier for AI in diabetes management, grappling with the world's highest regional prevalence amid resource constraints, urbanization, and mobile tech leaps. AI tools focus on affordable screening, telemedicine, and apps to bridge gaps in underserved areas. Urban hospitals in UAE/South Africa deploy cloud hybrids like Glooko for CGM dashboards, integrating with local EMRs to cut hypo events 30%. On-premises servers handle retinopathy AI screening (95% sensitivity) in resource hubs like Riyadh or Johannesburg. Public systems emphasize population analytics for T2D cohorts. ## Competitive Benchmarking Many global, regional, and local vendors characterize the AI in Diabetes Management Market. The global industry is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in technology, frequent changes in government policies, and environmental regulations are key factors that confront market growth.  The vendors compete based on cost, product quality, reliability, and government regulations. Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market. The major players in the global market Include Eli Lilly and Company, AstraZeneca, Sanofi, Novo Nordisk A/S, Tandem Diabetes Care, Inc., F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Dexcom, Inc., Insulet Corporation strategic market developments and decisions to improve operational effectiveness. ## Recent News & Developments **March 2025**: Insulet Corporation Commercially available in Australia; launching soon in Belgium, Canada, and Switzerland. Expanded sensor integrations with Dexcom G6/G7 and Abbott Freestyle Libre 2 Plus. Plans to launch in Israel, Saudi Arabia, UAE, Qatar, and Kuwait. First tubeless AID system communicating with CGM, automatically adjusts insulin every 5 minutes, improves clinical outcomes, waterproof Pod, wearable, controlled via smartphone or Omnipod Controller. **June 2025**: Medtronic announced a $50M investment over five years to open a Diabetes Global Capability Center in Pune, India, creating 300 jobs. It also plans to spin off its diabetes business as a standalone company named “MiniMed” to enhance strategic focus and innovation in diabetes care. **May 2024**: Sanofi, Formation Bio and OpenAI are collaborating to build AI-powered software to accelerate drug development and bring new medicines to patients more efficiently. The three teams will bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development lifecycle. This represents a first collaboration of its kind within the pharma and life sciences industries. Sanofi will leverage this partnership to provide access to proprietary data to develop AI models as it continues its path to becoming the first biopharma company powered by AI at scale. ## Report Scope | Market Size 2024 | 1,568.64 (USD Million) | | --- | --- | | Market Size 2025 | 1,925.66 (USD Million) | | Market Size 2035 | 14,239.56 (USD Million) | | Compound Annual Growth Rate (CAGR) | 11.76% (2025 - 2035) | | Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | Base Year | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2023 | | Market Forecast Units | USD Million | | Key Companies Profiled | Eli Lilly and Company, AstraZeneca, Sanofi, Novo Nordisk A/S, Tandem Diabetes Care, Inc., F. Hoffmann-La Roche Ltd, Abbott, Medtronic, Dexcom, Inc., Insulet Corporation. | | Segments Covered | By Type, By Deployment, By Application, By End User | | Key Market Opportunities | Expansion of Remote Patient Monitoring (RPM) and Telehealth. Emergence of Generative AI and Predictive Analytics. Partnerships Between Tech Giants and Healthcare Providers. | | Key Market Dynamics | Advancements in Connected Devices and Digital Health Infrastructure. Shift Toward Personalized and Predictive Healthcare. Increased Adoption of Cloud and SaaS Healthcare Platforms. Limited Interoperability Across Devices and EHR Systems. | | Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. | ## Frequently Asked Questions **Q: What is the projected market valuation for the AI in Diabetes Management Market by 2035?** A: The global market is projected to reach a valuation of 15.44 USD Billion by 2035. **Q: What was the global market valuation for the AI in Diabetes Management Market in 2024?** A: The overall market valuation was 1.188 USD Billion in 2024. **Q: What is the expected CAGR for the AI in Diabetes Management Industry during the forecast period 2025 - 2035?** A: The expected CAGR for the market during this period is 26.26%. **Q: Which segment is projected to have the highest valuation in the AI in Diabetes Management Market by 2035?** A: The Type 2 Diabetes segment is projected to have the highest valuation, reaching 10.0 USD Billion by 2035. **Q: What are the key applications of Artificial Intelligence in Diabetes Management?** A: Key applications include Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes, with Type 2 Diabetes leading in market size. **Q: Which deployment model is expected to dominate the AI in Diabetes Management Industry?** A: The Software as a Service (SaaS) model is expected to dominate, with a projected valuation of 6.78 USD Billion by 2035. **Q: Who are the leading companies in the global market?** A: Key players include Abbott Laboratories, Medtronic, Roche, and Dexcom, among others. **Q: What is the projected valuation for the Patient Self-Management segment by 2035?** A: The Patient Self-Management segment is projected to reach a valuation of 5.0 USD Billion by 2035. **Q: How does the global industry for Diabetes Treatment Centers compare to other end users?** A: The Diabetes Treatment Centers segment is projected to reach 3.0 USD Billion by 2035, indicating substantial growth. **Q: What is the anticipated growth trend for the Data Management segment in the AI in Diabetes Management Market?** A: The Data Management segment is expected to grow to 3.0 USD Billion by 2035, reflecting increasing demand for data-driven solutions. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-diabetes-management-market-26893*